MLN2201 is a humanized monoclonal antibody inhibitor that targets Integrinbeta2. It can inhibit reperfusion injury following a stroke and is applicable for researching inflammatory conditions such as ischemic stroke.
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted